Quarterly report Q1 2026

The information was provided for publication on May 26, 2026.

PROLIGHT
Diagnostics you can count on

TABLE OF CONTENTS

First quarter, January 1 – March 31, 2026

(Figures in parentheses refer to the corresponding period in the previous year.)

- Net sales amounted to 0 (0).
- Other operating income amounted to 1,201 (1,662) thousand SEK.
- Operating profit (EBIT) amounted to -10,389 (10,937) thousand SEK.
- Profit after tax amounted to -10,389 (-10,937) thousand SEK.
- Earnings per share before and after dilution: -0.86 (-1.55) SEK.
- Cash flow from operating activities was -12,640 (-9,176) thousand SEK.

Significant events during the quarter

- Scale-up of cartridge manufacturing at FlexMedical Solutions.
- Strong interest in the Psyros POC system at the international WHX Labs congress.
- Positive results reported for traumatic brain injury (TBI) biomarkers in collaboration with BRAINBox Solutions, confirming broad platform potential.

Significant events after the end of the period

- Selected as semi-finalist in the ADLM 2026 Disruptive Technology Award Competition.
- Secures second patent in Japan for the Psyros technology.
- Design freeze achieved for the Psyros instrument.

Financial calendar

August 27, 2026
Interim Report Q2

November 26, 2026
Interim Report Q3

February 25, 2027
Year End Report

May 26, 2027
Interim report Q1

CEO statement

Psyros® – The Next Generation Point-of-Care Platform

The first quarter of 2026 was characterized by continued focus on advancing the Psyros platform into the final stage ahead of clinical validation and commercialization. During the period, efforts were concentrated on finalizing the instrument and ensuring that the system meets the requirements for scalable manufacturing and use in clinical settings.

Following the end of the quarter, we achieved a key milestone with the formal design freeze of the instrument. This marks a major and decisive step toward industrialization of the platform and enables pilot production of instruments to be used for verification, validation, and the regulatory clinical performance study. The final development work leading up to the completed instrument design has resulted in improved robustness and manufacturability.

Following the end of the quarter, we received approximately SEK 11 million in R&D tax return from the UK tax authorities (HMRC). This is a significant amount that strengthens our cash position.

Market interest in the Psyros platform remained strong during the beginning of 2026. In discussions with potential industrial partners and clinical users, as well as at international congresses such as WHX Labs in Dubai in February, the system was met with very strong and clear interest, particularly regarding the combination of ultra-sensitive analytical performance, rapid turnaround times, and unique opportunities for cost-efficient manufacturing of disposable cartridges.

These interactions with end users and customers confirm that the Psyros system meets the market's demanding commercial requirements, while also demonstrating strong demand for the platform across several prioritized clinical application areas. A clear example is the collaboration with the U.S.-based company BRAINBox Solutions, which has demonstrated how rapidly new biomarkers can be integrated onto the Psyros platform. We are now entering the next phase, which is fully funded by BRAINBox, where 260 clinical samples from their pivotal HeadSMART II study will be analyzed. The results will provide important data for the continued evaluation of the collaboration and the platform's potential.

A further external validation of the potential of the proprietary Psyros technology is that Prolight was recently selected as a semifinalist in the Disruptive Technology Award Competition 2026, organized by the international Association for Diagnostics & Laboratory Medicine congress in the United States.

In parallel, work on the Psyros patent portfolio has continued. Following the end of the quarter, we received an additional positive patent notification in the strategically important Japanese market. This second patent application expands the scope of protection for Psyros' core technology and is particularly relevant for rapid tests based on swab samples, for example in infectious diseases such as influenza, RSV, or COVID-19.

Overall, we have received highly positive feedback from many international companies within the industry, as well as from end users who see Psyros as a potential next-generation point-of-care platform. We are frequently told how remarkably fast our small and cost-efficient organization has succeeded in advancing this complex and technically demanding product development program, where many large global companies have failed.

Our upcoming milestones include validating the manufacturing process for the cartridges, initiating pilot production of instruments corresponding to the final commercial product, verifying the POC system, and commencing the final clinical performance study in Europe and the UK.

Finally, I would like to thank our employees, partners, and shareholders for your continued support.

Lund May 26, 2026

Ulf Bladin
CEO Prolight Diagnostics (publ)

Safe point-of-care test enable faster diagnostics

Prolight Diagnostics has, over a long period, observed a sharply increasing demand in the market for user-friendly and near-patient analysis systems, so-called Point-of-Care ("POC") systems. A couple of examples are the mergers and acquisitions that have taken place. For example, Roche's acquisition of LumiraDx for 295 MUSD 2023 and bioMerieux's purchase of Spinchip in 2025 for 138 MEURO and the purchase of Specific Diagnostics for 417 MUSD in 2022. Additionally, Thermo Fisher Scientific's acquisition of Mesa BioTech in 2021 for USD 450 million and Abbott's acquisition of Alere for USD 5.8 billion already in 2016 show the greatly increased interest.

Primary and elderly care, emergency departments and ambulances demand fast, reliable blood test results when the patient is first examined instead of being forced to submit blood samples to hospital laboratories and wait hours or days for results, which is currently the case. Access to point-of-care analyses is especially important in acute conditions, such as for patients exhibiting acute chest pain and suspected myocardial infarction. In these situations, it is critical to make an early and correct diagnosis and initiate adequate treatment to save lives.

To meet this demand, Prolight is developing a new and flexible POC system, Psyros, which can perform In-Vitro Diagnostic (IVD) tests with the same sensitivity and precision as hospital laboratories but with the difference that test results can be given already within ten minutes or less. By obtaining these test results early in the patient care continuum, doctors and healthcare professionals can make the correct diagnosis and prioritise adequate resources for the right patient. As a result, substantial cost savings can also be realised in the heavily burdened healthcare system.

The new digital immunoassay technology was incorporated into Prolight in early 2022 through the acquisition of the British company Psyros Diagnostics Ltd, which has developed a new, cutting-edge POC technology for digital immunoassay. The wholly owned subsidiary Psyros Diagnostics currently has a highly competent team with long and broad experience in IVD development, especially in POC tests and POC systems. The team has unique competencies and experiences vital to the company's continued development.

Prolight's pioneering IP-protected POC technology counts individual molecules digitally from a drop of blood. This proprietary technology, which also has the possibility of multiplexing (testing several biomarkers at the same time), enables the measurement of biomarkers with extremely low detection levels (femtomolar 10-15) within approximately 10 minutes or less. To Prolight's knowledge, there is no other existing digital POC system deemed capable of performing these analyses at extremely low concentrations with such simplicity, precision, and low production costs. The system consists of an easy-to-use disposable cartridge and a portable analysis unit. Only a drop of blood is required to perform the test.

The cutting-edge technology will first be used to develop a diagnostic POC test that measures the protein troponin with high sensitivity and accuracy to aid in the rule-in and rule-out of myocardial infarction. By measuring the biomarker troponin, which is released from the heart into the bloodstream during the acute phase of myocardial infarction, the test helps to make a rapid diagnosis. Elevated levels of the protein troponin in the blood are a sign of damage in the heart muscle cells. The test places great demands on sensitivity and precision and has a substantial global sales potential.

The technology also opens up the possibilities of being able to develop and analyze new POC tests in a number of different clinical areas that were previously only possible to carry out in specialized laboratories. Prolight has been able to demonstrate that its digital ultra-sensitivity immunoassay can measure low levels of specific proteins down to single-digit nanograms per liter (ng/L) with laboratory-grade reproducibility. These concentrations are indicative of what is required to rule out myocardial infarction with high-sensitivity troponin assays[1].

Proof-of-performance results were obtained partly in November 2022 by measuring the levels of thyroid-stimulating hormone (TSH) in human plasma samples, partly in June 2023 by measuring high-sensitivity troponin in serum samples, and also

in November 2023 when the company was able to show that the system for detecting single molecules provides equivalent performance in whole blood compared to plasma, without the need to separate the cells from the sample. This reduces complexity and paves the way for an extremely competitive price level.

The final development work focuses on optimizing the IP-protected POC technology for digital immunoanalysis. An extensive preclinical evaluation of approximately 30 instrument prototypes confirmed the system's technical performance and provided a strong basis for implementing a limited number of targeted improvements focused on long-term robustness and scalability. In April 2026, the Company formally achieved design freeze for the instrument, marking a major and decisive step towards scalable manufacturing and clinical use. The completed design enables pilot production of instruments to be used for verification and validation, followed by the regulatory clinical performance study in Europe and the UK, and subsequently in the United States.

In March 2026, positive results were announced from a collaboration with BRAINBox Solutions, a leading developer of multimodal diagnostic and prognostic tests for traumatic brain injury (TBI).

The analytical evaluation demonstrated strong performance for a unique combination of three TBI biomarkers, highlighting how readily new markers can be transferred onto the Psyros platform, which is based on single-molecule counting. This further strengthens the platform's potential to improve patient care across a broad range of clinical applications.

The results are consistent with previously reported preclinical data demonstrating the ability of Psyros to deliver laboratory-quality results, detecting biomarkers at extremely low concentrations within minutes using only a small sample volume. The study was fully funded by BRAINBox, headquartered in Richmond, Virginia.

Based on these results, Prolight and BRAINBox are now advancing to the next phase of the BRAINBox-funded programme, in which all three assays will be evaluated using a biobank comprising 260 patient samples.

These samples represent a subset of more than 2,000 samples available from BRAINBox's ongoing pivotal registration study, HeadSMART II, which is evaluating the company's diagnostic and prognostic test for mild traumatic brain injury, BRAINBox TBI, in preparation for regulatory submission to the U.S. Food and Drug Administration (FDA). The assay format utilises Psyros multiplex-capable test cartridges with dry reagents, enabling scalable and cost-efficient manufacturing—an important advantage in TBI and other conditions requiring high-precision measurement of multiple analytes.

Vision & Strategy

Vision

Prolight Diagnostics develops pioneering, innovative Point-Of-Care (POC) systems, for quick and reliable diagnosis of acute events, initially for myocardial infarction.

We offer our innovative POC systems to companies with global sales organisations in relevant POC segments.

Strategy

With Prolight's high sensitive Troponin POC system, the ambition is to have test results available to doctors within ten minutes to allow rapid diagnosis and treatment when the patient is examined the first time, instead of spending critical time waiting for results from a hospital laboratory. This could be, for example, in an emergency department, a healthcare centre, an ambulance, or a care home.The ability to rule-in or rule-out myocardial infarction early in the care pathway will contribute to an efficient treatment for the right patients, allowing significant cost savings.

Initially, the focus will be on the measurement of the cardiac biomarker troponin, with high sensitivity and precision, which has a substantial global sales potential. The intention is also to include more biomarkers in many diverse clinical areas on the company's platform if they are deemed to be strategically and economically beneficial.

Point-of-Care

Point-of-Care – a rapidly growing global market

There is an acute awareness of the value of rapid, accurate, and efficient testing near the patient. The market demands that more tests are moved out from large hospital laboratories and closer to the patient and care giver. POC tests can also help reduce healthcare costs by giving faster results and more rapid treatment. Throughout the Covid pandemic, the use of POC testing increased substantially. This led to an acute awareness of the value of rapid, simple, and efficient testing and analysis near the patient. Most companies, healthcare providers, politicians and the general public realize the value of these tests, benefitting patients, clinicians, and healthcare in general. This interest has, in turn, created a need for new technologies that can meet the challenges of more demanding tests, whilst still being competitively priced.

According to Precedence research, the POC market is expected to grow from approximately USD 39.6 billion in 2024 to approximately USD 125.3 billion in 2034[2].

The global market for cardiac biomarkers
The global market for cardiac biomarkers was approximately USD 11.5 billion in 2024 and is expected to grow by approximately 7.2 percent per year until 2033[3].

Regarding POC tests for cardiac biomarkers, the market is driven by an increase in the number of people with heart disease and a growing awareness of the importance of early diagnosis to deliver timely and targeted care to the right patients.

The global market for troponin
The global market for troponin was approximately USD 1.6 billion in 2024 and is expected to grow by approximately 12.6 percent per year until 2033, reaching an estimated USD 4.2 billion by 2033[4].

Trends favoring the market development of POC tests
The main driving forces behind the general growth of POC tests are considered to be increased demand for central laboratory tests that are moved closer to the patient, e.g. to emergency departments, primary care, ambulances and nursing homes, rapid technical development, digitization within healthcare, increasing investments in research and development as well as an ageing population in the West.

[2] https://www.precedenceresearch.com/point-of-care-testing-market

[3] IMARC Group, IMARC group 2025: https://www.imarcgroup.com/cardiac-biomarkers-market

[4] https://www.custommarketinsights.com/press-releases/troponin-market-size/

Global market and Compound Annual Growth Rate (CAGR)



Groundbreaking ultra-sensitive POC technology

Prolight is poised to deliver the most innovative and best-in-class POC systems on the market

Prolight is well-positioned to deliver POC systems to satisfy several clinical unmet needs. These include high sensitive troponin, other biomarkers in many diverse clinical areas as well as assays currently not available at POC and multiplex assays for measuring several analytes simultaneously.

A new ground-breaking POC technology for digital immunoassay
Prolight has an entirely novel cutting-edge POC technology for digital immunoassay, which can count individual molecules from a single drop of blood. The unique IP-protected technology opens the possibility of developing several new POC tests and analysis in a wide range of clinical areas where many of them previously have only been possible to analyse in specialised laboratories. Further advantages of the digital immunoassay include its simplicity and low production costs.

Detection limit at the level of PCR tests, but with significantly faster response time
Today, PCR tests are recommended to confirm Covid, but the response time is lengthy, sometimes several hours to days, depending on the system. By using our digital assay technology, it is possible to count individual molecules at low levels, including viral particle proteins, such as coronavirus. As a result, sensitivity and accuracy can be as good or better than PCR tests currently offered on large central laboratory instruments. The large and highly significant difference between today's PCR tests and Prolight's innovative digital POC platform is that the response time can be reduced to just ten minutes or less.

May be the start of a paradigm shift in POC testing
This novel technology could mark the beginning of a paradigm shift in POC testing for clinical diagnostics. Some examples of possible future clinical areas are: Neuropathology (dementia, traumatic brain injuries), Immune system dysfunction (sepsis, autoimmune diseases), Sexually Transmitted Infections, Rapid virus detection such as Covid. The unique and IP-proteced technology behind the digital immunoassay will make it possible to test a range of biomarkers with high sensitivity and accuracy on a single POC instrument. Prolight believes that this technology could be a paradigm shift in POC testing for clinical diagnostics.

Next generation point of care platform
Future applications across many diverse clinical areas

Prolight has a strong patent portfolio

The patent portfolio for the Psyros single molecule counting technology
Prolight have six families of patent applications relating to the Psyros single-molecule-counting technology. The first five families are currently in the national / regional phases in a range of territories worldwide. The sixth patent application entered the PCT (patent cooperation treaty) international phase in November 2025.

The first 2 patents were granted in Europe in Q2 2025 by the European Patent Office (EPO) and have now been validated in the following 17 European jurisdictions: France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Belgium, Ireland, the Netherlands, Portugal, Sweden, Switzerland, Turkey, Denmark, Finland and Norway. This covers a population base of 540 million people. A third patent was granted in Europe in December 2025 and is currently going through the validation process.

The core patent for Psyros was granted by the Japan Patent Office (JPO) in July 2025 and in April 2026, a notice of allowance was received for the second patent for the Psyros technology in Japan.

Family 1 patents EP3987287 and JP7700055 protect the core technology and will remain in force until 2040.

Family 2 patent EP4264266 is an enhancement to the core technology and will remain in force until 2041.

Family 3 patent EP4496995 uses 2 wavelengths to enhance signal generation and will remain in force until 2042.

A divisional application of family 1 patent EP3987287 has also been filed (published as EP4549943) to seek greater scope for the core technology.

The patent situation for MicroFlex
For MicroFlex, the patent portfolio consists of six registered patents (three in the US, two in the EU, and one in Sweden) and three patent applications that have advanced to the national phase and are now being pursued in various territories.

One of the patent applications pertains to how the sampling tube can be directly integrated into the cartridge. This enables a very simple workflow for all types of clinical environments. No specially trained personnel are needed to pipette and centrifuge the blood sample. MicroFlex thus creates the conditions to offer a fully automated platform for immunodiagnostics.

The most recently approved patent in the United States in May 2025 provides protection for the unique technical composition of the MicroFlex analytical device and reaction chamber. The patent is a testament to the technological height of MicroFlex.

The approved patent from October 2024 concerns a European patent based on a groundbreaking solution for separating plasma from whole blood in a liquid-based consumable. The separation produces high-quality plasma, requires minimal physical space, and is performed in a short amount of time, unlocking new potential business opportunities by integrating the technology into other liquid-based disposable systems

About PCT and patent application process
Patent Cooperation Treaty (PCT) is an international agreement that allows you to obtain, with a single application, in one language, a novelty search and preliminary patentability assessment conducted by one authority for approximately 150 countries. For a PCT application to lead to a patent in a particular country (or territory, such as the EU), the application must be prosecuted at the respective patent office.

During the patent application process, it is normal for the reviewing authority to ask several questions, which Prolight and the company's legal representatives spend much time answering to achieve the strongest possible patent protection. This correspondence takes different amounts of time depending on each authority's questions. It is, therefore, challenging to give an exact date for when an individual patent application can be expected to be approved.

Owners

Owners list as of 2026-03-31

	Holdings 2026-03-31	Votes in %
FÖRSÄKRINGSAKTIEBOLAGET AVANZA PENSION	714,974	5.94
NORDNET PENSIONSFÖRSÄKRING AB	508,681	4.22
INTEGRATED TECHNOLOGIES LTD	493,720	4.10
STEVEN ANDREW ROSS	324,782	2.70
AILEEN JANE MCGETTRICK	318,295	2.64
PAUL BRENDAN MONAGHAN	318,295	2.64
JULIE RICHARDS	318,295	2.64
SWEDBANK FÖRSÄKRING AB	226,178	1.88
SEB LIFE INTERNATIONAL ASSURANCE	225,380	1.87
FREDRIK ALPSTEN	205,766	1.71
Total, 10 largest owners	**3,644,277**	**30.26**
Other	8,400,505	69.74
Total	**12,044,782**	**100.00**

Source: Euroclear

The company has outstanding warrants to employees of Psyros Diagnostics Ltd. of 8,304,510 (corresponding to 83,045 shares) and 80,703 (corresponding to 80,703 shares) and can thus cause dilution.

Prolight Diagnostics' share is traded on the NGM Growth Market, under the name PRLD.

The Group's development during quarter 1, January 1 – March 31,2026

(figures in parentheses refer to the corresponding period in the previous year)

INCOME

- During the product development period, the Group has no sales and net turnover.
- Other income for the quarter amounted to SEK 1,201 (1,662) thousand, consisting mainly of contributions received and income from the partner BRAINBox in the English subsidiary Psyros.

COSTS AND RESULTS

- The Group's total operating expenses during the quarter amounted to SEK 20,675 (15,371) thousand. The increase in operating expenses consists mainly of external costs related to the development of the Group's products.
- Capitalized work for own account amounted to SEK 9,084 (2,772) thousand and refers to costs for the Group's product development in the English subsidiary Psyros.

FINANCING AND CASH FLOW

- Cash flow from operating activities amounted to -12,640 (-9,176) thousand SEK.
- The Group's cash flow from investing activities amounted to -10,805 (-2,911) thousand SEK and mainly consists of capitalized development costs of 9,084 (2,772) thousand SEK linked to the Group's product development in the English subsidiary.
- The total cash flow for the quarter was -23,445 (-12,087) thousand SEK.
- Cash and cash equivalents at the end of the quarter amounted to 17,262 (3,173) thousand SEK. During April 2026, i.e. after the end of the quarter, the English subsidiary Psyros has received 11 million SEK in "R&D tax credit" which improved liquidity by the same amount.

EQUITY, RECEIVABLES AND LIABILITIES
(figures in brackets refer to 2025-12-31)

- Equity in the Group amounted to 159,121 (169,347) TSEK as of 31 March 2026.
- Provisions amounted to 14,419 (14,419) TSEK and consist of a deferred tax liability regarding the acquired technology platform in the English subsidiary Psyros.
- Current receivables amounted to 19,748 (17,201) TSEK.
- Current liabilities amounted to 9,380 (9,664) TSEK.
- Total assets as of March 31, 2026 amounted to 182,920 (193,431) TSEK and consist mainly of acquired intangible assets of 69,994 (69,994) KSEK relating to the technology platform in Psyros Diagnostics Ltd. and intangible assets of 66,379 (57,297) KSEK relating to capitalized work for own account.
- The equity ratio was 87 percent (76).

Parent company development during quarter 1, January 1 – March 31, 2026

(figures in parentheses refer to the corresponding period in the previous year)

INCOME

- Other income for the quarter amounted to 790 (787) KSEK. The income consisted mainly of invoiced costs to Psyros for corporate management services, exchange rate gains and distribution income from NGM.

COSTS AND RESULTS

- The company's total operating expenses during the quarter amounted to 2,714 (2,075) thousand SEK. The costs consisted mainly of external costs regarding consulting costs for corporate management services.
- The result for the quarter amounted to -1,924 (-1,288) thousand SEK.

FINANCING AND CASH FLOW

- Cash flow from operating activities during the quarter amounted to -23,415 (-12,341) thousand SEK.
- The total cash flow for the quarter amounted to -23,415 (-12,341) thousand SEK.
- Liquid funds at the end of the quarter amounted to 16,035 (2,489) thousand SEK.

EQUITY, RECEIVABLES AND LIABILITIES
(figures in brackets refer to 2025-12-31)

- Equity amounted to 91,131 (93,055) TSEK as of March 31, 2026.
- Total assets amounted to 94,667 (95,736) TSEK as of March 31, 2026 and consist mainly of shares in Psyros Diagnostics Ltd of 55,768 (55,768) TSEK.
- The equity ratio was 96 percent (81).

Other information

RISKS AND UNCERTAINTIES
Prolight Diagnostics' operations are exposed to a number of risks and uncertainties, which to varying degrees may have a negative impact on the continued operation. Both external, operational and financial risks may have a negative impact on the company in the short and long term. Prolight continuously works to inventory and manage the risks and uncertainties that the business is exposed to in order to limit risk exposure and any impact if a risk arises. A detailed description of risks and risk management can be found in the Annual Report for 2025.

ACCOUNTING PRINCIPLES
This interim report has been prepared in accordance with Chapter 9 of the Annual Accounts Act. Prolight applies the General Guidelines of the Swedish Accounting Standards Board 2012:1 (K3) when preparing the company's financial reports.

AUDITOR'S REVIEW
The quarterly report has not been subject to an auditor's review.

RELATED PARTY TRANSACTIONS
No significant related party transactions have been carried out during the period except with the company's CEO and CFO. The transactions have been carried out on market terms.

OTHER
The company has outstanding warrants to employees of Psyros Diagnostics Ltd. of 8,304,510 (equivalent to 83,405 shares) and 80,703 (equivalent to 80,703 shares) which may therefore result in dilution.

Prolight Diagnostics' share is traded under the ticker symbol PRLD on the NGM Growth Market.

GROUP FINANCIAL STATEMENTS

Income Statement, Summary Group

Amount in TSEK	Jan-Mar 2026	Jan-Mar 2025	Full Year 2025
Operating income etc			
Net Sales	0	0	0
Activated work for own account	9,084	2,772	15,349
Other income	1,201	1,662	26,854
Total income	10,286	4,434	42,203
Operating expenses			
Other external costs	-14,311	-9,477	-53,296
Personnel costs	-5,782	-5,475	-22,503
Write-down intangible assets	-580	-418	-19,635
Other operating expenses	-2	-1	-18
Total expenses	*-20,675*	*-15,371*	*-95,452*
Operating result (EBIT)	**-10,389**	**-10,937**	**-53,249**
Result from financial investments			
Other interest income and similar items	0	0	492
Other interest expenses and similar items	0	0	-323
Total result from financial investments	*0*	*0*	*169*
Taxes	0	0	3,372
Net loss	**-10,389**	**-10,937**	**-49,708**

Balance Sheet, Summary Group

Amount in TSEK	2026-03-31	2025-03-31	2025-12-31
ASSETS			
Subscribed but not paid-in capital	**0**	**0**	**90**
Fixed assets			
Intangible assets			
Capaitalized expenditure on development work and similar work	136,360	132,463	127,276
Patent	14	21	15
	136,374	*132,484*	*127,291*
Tangible assets			
Equipment, tools, fixtures and fittings	9,536	5,825	8,243
	9,536	5,825	8,243
Total fixed assets	*145,910*	*138,309*	*135,534*
Current assets			
Other receivables	19,634	11,115	14,409
Prepaid expenses and accrued income	114	86	2,792
Cash and cash equivalents	17,262	3,173	40,606
Total current assets	*37,010*	*14,374*	*57,807*
Total assets	**182,920**	**152,683**	**193,431**
Equity			
Share capital	120,448	70,209	120,448
Other paid in capital	279,881	237,870	279,881
Retained earnings	-230,819	-180,664	-181,274
Loss for the period	-10,389	-10,937	-49,708
Total equity	*159,121*	*116,478*	*169,347*
Provisions			
Accrued tax liabilities	14,419	17,791	14,419
Total Provisions	*14,419*	*17,791*	*14,419*
Current liabilities			
Accounts payables	5,901	2,089	6,351
Other liabilities	872	13,463	849
Accrued expenses and deferred income	2,606	2,862	2,464
Total current liabilities	*9,380*	*18,414*	*9,664*
Total equity and liabilities	**182,920**	**152,683**	**193,431**

Changes in shareholders equity, Group

Amount in TSEK	Share capital	Other paid in capital	Other capital incl result for the period	Total shareholders equity
Shareholders equity 2026-01-01	**120,448**	**279,880**	**-230,981**	**169,347**
Loss for the period			-10,389	-10,389
Foreign exchange rate adjustment			163	163
Shareholders equity 2026-03-31	**120,448**	**279,880**	**-241,207**	**159,121**

Amount in TSEK	Share capital	Other paid in capital	Other capital incl result for the period	Total shareholders equity
Shareholders equity 2025-01-01	**70,209**	**237,870**	**-179,794**	**128,285**
Issue of new shares	50,239	50,148		100,387
Issuance cost		-8,139		-8,139
Loss for the period			-49,708	-49,708
Foreign exchange rate adjustment			-1,479	-1,479
Shareholders equity 2025-12-31	**120,448**	**279,880**	**-230,981**	**169,347**

Cash flow statement, Group

Amount in TSEK	Jan-Mar 2026	Jan-Mar 2025	Full Year 2025
OPERATING ACTIVITIES			
Operating result (EBIT)	-10,389	-10,937	-53,249
Adjustment	580	418	7,079
Interests received	0	0	492
Cashflow from operating activities before changes in working capital	*-9,809*	*-10,519*	*-45,678*
Cash flow from changes in working capital			
Decrease(+)/increase (-) in operating receivables	-2,547	3,184	-4,261
Decrease (-)/Increase (+) in operating liabilities	-284	-1,841	12,934
Total Cash flow from changes in working capital	*-2,831*	*1,343*	*8,673*
Cash flow from operating activities	**-12,640**	**-9,176**	**-37,005**
INVESTMENT ACTIVITIES			
Investment in intangible assets	-9,084	-2,772	-15,349
Investment in tangible assets	-1,721	-139	-4,381
Cash flow from investment activities	**-10,805**	**-2,911**	**-19,730**
FINANCING ACTIVITIES			
Issue of new shares	0	0	81,437
Cash flow from financing activities	**0**	**0**	**81,437**
Cash flow for the period	**-23,445**	**-12,087**	**24,702**
Cash and equivalents at the beginnging of period	40,606	15,734	15,734
Exchange rate differences in cash	101	-474	170
Cash and equivalents at the end of period	**17,262**	**3,173**	**40,606**

Key ratio Group

	Jan-Mar 2026	Jan-Mar 2025	Full Year 2025
Net Sales, MSEK	-	-	-
Cash and equivalents, MSEK	17.3	3.1	40.6
Equity ratio, %	87	76	88
Quick asset ratio, %	395	78	598
Number of shares in the beginning of period	12,044,782	7,020,895	7,020,895
Average number of shares in the period	12,044,782	7,020,895	11,877,896
Number of shares in the end of period	12,044,782	7,020,895	12,044,782
Profit/Loss, MSEK	-10.4	-10.9	-49.7
Earnings per share, SEK*	-0.86	-1.55	-4.13
Earnings per share after dilutions, SEK*	-0.86	-1.55	-4.13

* In 2025, a reverse split has been carried out.

THE PARENT COMPANY'S FINANCIAL STATEMENTS

Income Statement, Summary Parent company

Amount in TSEK	Jan-Mar 2026	Jan-Mar 2025	Full Year 2025
Operating income etc.			
Net Sales	0	0	0
Other income	790	787	3,283
Total operating income	*790*	*787*	*3,283*
Operating expenses			
Other external costs	-2,345	-1,707	-7,785
Personnel costs	-368	-368	-1,423
Amortization intangible assets	0	0	-1,836
Other operating expenses	-2	-1	-18
Total operating expenses	**-2,714**	**-2,075**	**-11,063**
Operating result	**-1,924**	**-1,288**	**-7,780**
Result from financial investments			
Write-down of investment in subsidiary	0	0	-61,385
Other interest income and similar items	0	0	492
Other interest expenses and similar items	0	0	-323
Total result from financial investments	**0**	**0**	**-61,216**
Net loss	**-1,924**	**-1,288**	**-68,996**

Balance Sheet, Summary, Parent company

Amount in TSEK	2026-03-31	2025-03-31	2025-12-31
ASSETS			
Subscribed but not paid-in capital	**0**	**0**	**90**
Fixed assets			
Capitalized expenditure on development work and similar work	0	1 836	0
Participation in group companies	55,768	68,768	55,768
Total fixed assets	*55,768*	*70,604*	*55,768*
Current assets			
Other receivables	293	235	300
Receivables from group company	22,458	11,088	0
Prepaid expenses and accrued income	114	86	128
Cash and cash equivalents	16,035	2,489	39,450
Total current assets	*38,900*	*13,898*	*39,878*
Total assets	**94,667**	**84,502**	**95,736**
Equity			
Restricted equity	133,495	83,256	133,495
Profit or loss brought forward / Loss for the year	-42,364	-14,744	-40,440
Total equity	*91,131*	*68,512*	*93,055*
Current liabilities			
Accounts payables	1,024	177	406
Other liabilities	0	13,000	0
Accrued expenses and deferred income	2,512	2,813	2,275
Total current liabilities	*3,536*	*15,990*	*2,681*
Total equity and liabilities	**94,667**	**84,502**	**95,736**

Changes in shareholders equity, Parent company

	Restricted equity		Non resticted equity		
Amount in TSEK	Share capital	Statutory reserve	Share premium reserve	Profit/loss brought forward	Total Shareholders equity
Shareholders equity 2026-01-01	**120,448**	**13,047**	**266,834**	**-307,274**	**93,055**
Loss for the period				-1,924	**-1,924**
Shareholders equity 2026-03-31	**120,448**	**13,047**	**266,834**	**-309,198**	**91,131**

	Restricted equity		Non resticted equity		
Amount in TSEK	Share capital	Statutory reserve	Share premium reserve	Profit/loss brought forward	Total Shareholders equity
Shareholders equity 2025-01-01	**70,209**	**13,047**	**224,823**	**-238,278**	**69,801**
Issue of new shares	50,239		50,149		**100,388**
Issuance cost			-8,138		**-8,138**
Loss for the period				-68,996	**-68,996**
Shareholders equity 2025-12-31	**120,448**	**13,047**	**266,834**	**-307,274**	**93,055**

Cash flow statement summary, Parent company

Amount in TSEK	Jan-Mar 2026	Jan-Mar 2025	Full Year 2025
THE ONGOING OPERATIONS			
Operating result	-1,924	-1,289	-7,780
Adjustment	0	-1	-1,224
Interest received	0	0	493
Cashflow from operating activities before changes in working capital	*-1,924*	*-1,290*	*-8,511*
Cash flow from changes in working capital			
Decrease (+)/increase (-) in operating receivables	-22,347	-11,049	-70
Decrease (-)/Increase (+) in operating liabilities	855	-2	215
Total cash flow from changes in working capital	*-21,492*	*-11,051*	*145*
Cash flow from operating activities	**-23,415**	**-12,341**	**-8,366**
INVESTMENT ACTIVITIES			
Capital contribution	0	0	-48,451
Total cash flow investment activities	**0**	**0**	**-48,451**
FINANCING ACTIVITIES			
Share issue	0	0	81,437
Cash flow from financing activities	**0**	**0**	**81,437**
Cash flow for the period	**-23,415**	**-12,341**	**24,620**
Cash and equivalents at the beginnging of period	39,450	14,830	14,830
Cash and equivalents at the end of period	**16,035**	**2,489**	**39,450**

Produkten är under utveckling. Design och specifikation kan ändras för den första produkten.

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Growth Market marketplace, under the ticker PRLD.

For further information, please contact:
Prolight Diagnostics AB (publ)
E-mail: info@prolightdx.com
Telephone: +46 73 582 39 87
Website: www.prolightdx.com/en/